预约演示
更新于：2025-07-21
Pegenzileukin
更新于：2025-07-21
概要
基本信息
原研机构 |
权益机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 611938424
来源: *****
关联
9
项与 Pegenzileukin 相关的临床试验NCT05535023
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx
CTR20220689
一项评估SAR444245（THOR-707）联合其他抗癌疗法治疗晚期和转移性胃肠癌受试者的临床获益的II 期、非随机、开放标签、多队列、多中心研究（Pegasus Gastrointestinal 203）
NCT05104567
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
100 项与 Pegenzileukin 相关的临床结果
登录后查看更多信息
100 项与 Pegenzileukin 相关的转化医学
登录后查看更多信息
100 项与 Pegenzileukin 相关的专利（医药）
登录后查看更多信息
2
项与 Pegenzileukin 相关的文献（医药）2024-10-01Cancer research communications
A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates
Article
作者: Shawver, Laura K. ; Milla, Marcos E. ; San Jose, Kristine M. ; Acuff, Nicole V. ; Leveque, Joseph A. ; Pena, Michael J. ; Caffaro, Carolina E. ; Buetz, Christen ; Herman, Rob W. ; Ma, Lina ; Pham, Helene V. ; Byers, Anthony M. ; Ismaili, Taylor K. ; Koriazova, Lilia K. ; Joseph, Ingrid B. ; Chen, David B. ; Sassoon, Ingrid ; Carrio, Roberto ; Cucchetti, Margot ; Ptacin, Jerod L. ; Mooney, Jill M. ; Pavlova, Yelena ; Aerni, Hans R.
Abstract:
We have created a precisely pegylated IL-2 [SAR-444245 (SAR’245) or pegenzileukin, previously THOR-707] designed for proliferation of target CD8+ T and NK cells for anticancer activity, with minimal expansion of anti-target regulatory CD4+ T cells (Treg) that counter their action, or eosinophils that trigger vascular leak syndrome (VLS). We performed in vivo studies in nonhuman primates (NHP) to monitor the safety of SAR’245, pharmacokinetic profile, and pharmacodynamic parameters including expansion of peripheral CD8+ T and NK cells, and effects on Tregs and eosinophils. Studies included multiple ascending dosing and repeat dosing with different regimens (QW, Q2W, Q3W and Q4W). We also conducted ex vivo studies using human primary cells to further evaluate SAR’245 stimulation of target cells alone and in combination with programmed cell-death 1 (PD-1) checkpoint inhibitors. The pharmacokinetic profile of SAR’245 in NHP demonstrated dose-proportional exposure that was comparable with redosing. It elicited expansion of peripheral CD8+ T and NK cells that was comparable with each dose and with multiple dosing regimens. Once-weekly dosing showed no significant adverse effects, including no hallmark signs of VLS at dosing levels up to 1 mg/kg. Ex vivo, SAR’245 enhanced T-cell receptor responses alone and in combination with PD-1 inhibitors without inducing cytokines associated with cytokine release syndrome or VLS. Results support the clinical development of SAR’245 as a drug candidate for the treatment of solid tumors, alone or in combination with PD-1 inhibitory agents.
Significance::
SAR-444245 (SAR’245, pegenzileukin) is an extended half-life IL-2 that targets effector CD8+ T and NK cells, with little effect on regulatory T cells. We show that in the nonhuman primate model that closely approximates human immune function and response to IL-2, SAR’245 selectively activates CD8+ T and NK effectors without significant serious side effects (vascular leak syndrome or cytokine release syndrome), suggesting its potential for the treatment of solid tumors in humans.
Nature communications1区 · 综合性期刊
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
1区 · 综合性期刊
ArticleOA
作者: Caffaro, Carolina E ; Pena, Michael J ; Koriazova, Lilia K ; Shawver, Laura K ; Ma, Lina ; Herman, Rob W ; Joseph, Ingrid B ; Pavlova, Yelena ; Chen, David B ; San Jose Gall, Kristine M ; Milla, Marcos E ; Aerni, Hans R ; Acuff, Nicole V ; Ptacin, Jerod L
Abstract:
The implementation of applied engineering principles to create synthetic biological systems promises to revolutionize medicine, but application of fundamentally redesigned organisms has thus far not impacted practical drug development. Here we utilize an engineered microbial organism with a six-letter semi-synthetic DNA code to generate a library of site-specific, click chemistry compatible amino acid substitutions in the human cytokine IL-2. Targeted covalent modification of IL-2 variants with PEG polymers and screening identifies compounds with distinct IL-2 receptor specificities and improved pharmacological properties. One variant, termed THOR-707, selectively engages the IL-2 receptor beta/gamma complex without engagement of the IL-2 receptor alpha. In mice, administration of THOR-707 results in large-scale activation and amplification of CD8+T cells and NK cells, without Treg expansion characteristic of IL-2. In syngeneic B16-F10 tumor-bearing mice, THOR-707 enhances drug accumulation in the tumor tissue, stimulates tumor-infiltrating CD8+T and NK cells, and leads to a dose-dependent reduction of tumor growth. These results support further characterization of the immune modulatory, anti-tumor properties of THOR-707 and represent a fundamental advance in the application of synthetic biology to medicine, leveraging engineered semi-synthetic organisms as cellular factories to facilitate discovery and production of differentiated classes of chemically modified biologics.
79
项与 Pegenzileukin 相关的新闻（医药）2025-06-30
细胞疗法免疫疗法临床1期临床终止临床结果
2025-04-16
·靶点圈
细胞疗法临床结果临床研究免疫疗法
2025-02-20
·医药速览
抗体药物偶联物
100 项与 Pegenzileukin 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HPV阳性的口咽鳞状细胞癌 | 临床2期 | 美国 | 2022-08-24 | |
| HPV相关的口咽肿瘤 | 临床2期 | 美国 | 2022-08-24 | |
| 肿瘤 | 临床2期 | 美国 | 2022-01-30 | |
| 食管腺癌 | 临床2期 | 美国 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 中国 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 比利时 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 智利 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 法国 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 意大利 | 2021-12-09 | |
| 食管腺癌 | 临床2期 | 荷兰 | 2021-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 138 | (Cohort A: ESCC Post PD-1/PD-L1: Pegenzileukin 24 mcg/kg + Pembrolizumab as 2/3L Therapy) | 醖網願鏇膚鹽遞蓋積鏇 = 鏇憲簾網選獵繭網獵鑰 醖遞製製糧壓齋鏇築憲 (築網窪願餘繭齋廠壓遞, 壓窪壓蓋鏇遞壓選構糧 ~ 膚窪選顧範簾壓齋夢遞) 更多 | - | 2025-07-01 | ||
Pegenzileukin24mcg+Pembrolizumab (CohortB1:GC/GEJ PD-1/PD-L1 naïve Non-MSI-H CPS>=1:Pegenzileukin24mcg/kg+Pembrolizumab as 1-3LTherapy) | 膚構窪範蓋獵鹽壓廠選 = 網艱壓齋顧觸膚網積壓 餘夢鹽壓鏇鑰網糧膚餘 (繭顧壓廠簾選餘範窪顧, 窪鏇醖製築襯膚憲窪願 ~ 範觸廠艱衊繭選觸築範) 更多 | ||||||
临床1期 | 晚期恶性实体瘤 cytokines | circulating DNA (ctDNA) | - | 遞鹹繭齋鑰獵廠蓋淵艱(製選壓膚繭齋襯糧築衊) = 淵願憲艱襯遞鑰範醖顧 遞積鏇鑰觸鹽範鏇壓艱 (願鬱襯糧鹽製選鹹願襯, 1.77–14.39) 更多 | - | 2024-11-05 | ||
遞鹹繭齋鑰獵廠蓋淵艱(製選壓膚繭齋襯糧築衊) = 選鏇襯鹹夢鏇衊鹽繭網 遞積鏇鑰觸鹽範鏇壓艱 (願鬱襯糧鹽製選鹹願襯, 1.04–8.01) 更多 | |||||||
临床1期 | 116 | (Arm A) | 廠憲簾範鹹憲範蓋蓋鏇(鬱鬱選餘夢範膚憲淵鹽) = 24 μg/kg 選鏇鑰遞齋齋壓壓憲醖 (衊餘蓋願夢繭構繭醖廠 ) 更多 | 积极 | 2022-09-10 | ||
(Arm B) | |||||||
临床1/2期 | 实体瘤 二线 | 28 | THOR-707 (8 µg/kg (n=4)) | 窪醖鑰廠顧鑰遞鏇網鹽(鏇衊餘蓋壓襯範網繭選) = 觸襯鹹鏇廠製醖艱醖餘 鏇衊築衊構憲夢鹽窪蓋 (鹹齋構獵蓋鏇淵積獵淵 ) 更多 | 积极 | 2021-04-10 | |
THOR-707 (8 µg/kg (n=4), 16 µg/kg (n=6), 24 µg/kg (n=7)) | 窪醖鑰廠顧鑰遞鏇網鹽(鏇衊餘蓋壓襯範網繭選) = 鏇遞網襯艱構衊糧艱艱 鏇衊築衊構憲夢鹽窪蓋 (鹹齋構獵蓋鏇淵積獵淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用